Company intelligence / Profile preview
Darnitsa
- Ownership
- Private
- Employees
- ~1100
- Development stage
- Other
Overview
Darnitsa has a broad commercial portfolio of over 180 products with a focus on cardiology, neurology and pain management. It was the first Ukrainian company licensed to produce Pfizer’s oral COVID‑19 treatment for low/middle-income countries and has begun acquiring technology for mRNA-based vaccines. The company continues to launch new products even during wartime disruptions.
No specific clinical trial results are published as the company primarily produces generics and established medicines.
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- small molecules (tablets, ampoules, sterile antibiotics)oral antivirals (e.g., nirmatrelvir/ritonavir)potential mRNA-based vaccines in development
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Darnitsa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Darnitsa.